Myriad Genetics (MYGN) Misses Q1 EPS by 2c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts MYGN Hot Sheet
Price: $3.05 -4.69%
Financial Fact:
Molecular diagnostic testing: 165.1M
Today's EPS Names:
XYF, SQZB, RENO, More
Financial Fact:
Molecular diagnostic testing: 165.1M
Today's EPS Names:
XYF, SQZB, RENO, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q1 EPS of ($0.09), $0.02 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $200.4 million versus the consensus estimate of $202.39 million.
GUIDANCE:
Myriad Genetics sees FY2026 revenue of $80.6-0.88 billion, versus the consensus of $1.53 billion.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Aggreko files for proposed IPO
- Gogoro Inc (GGR) Reports Q2 Loss of $0.24, Offers FY26 Revenue Guidance
- Philips prices €650M EU green bond due 2034
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
